Subbiah M T, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z
Department of Medicine, University of Cincinnati College of Medicine, OH 45267-0540.
J Clin Endocrinol Metab. 1993 Oct;77(4):1095-7. doi: 10.1210/jcem.77.4.8408459.
Coronary heart disease (CHD) is the leading cause of death in postmenopause. Estrogen administration in postmenopause lowers the risk of CHD by 50%. A variety of estrogen preparations are currently used in postmenopausal hormone replacement therapy. It is unknown, however, if structural differences in the estrogen molecule influence the cardioprotective effects of estrogens. In this communication we have shown that equine estrogens (especially equilin) exhibit higher antioxidant potency (as measured by fatty acids and sterols oxidation) when compared to estrone and estradiol-17 beta.
冠心病(CHD)是绝经后女性的主要死因。绝经后使用雌激素可使冠心病风险降低50%。目前,多种雌激素制剂被用于绝经后激素替代疗法。然而,雌激素分子的结构差异是否会影响其心脏保护作用尚不清楚。在本报告中,我们发现,与雌酮和17β-雌二醇相比,马雌激素(尤其是马萘雌酮)表现出更高的抗氧化能力(通过脂肪酸和甾醇氧化来衡量)。